Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemoglobin subunit mu is a member of the human globin gene family, specifically within the alpha globin gene cluster on chromosome 16. It encodes a 141-amino-acid polypeptide similar to delta globins found in non-mammalian species such as birds and reptiles. Although its mRNA is expressed at moderate levels, the actual protein has not been convincingly detected via mass spectrometry or other proteomic techniques[1][2]. Its evolutionary origin, previously as a pseudogene, and uncertain protein expression suggest that it may have little—if any—physiological role in humans apart from being a genomic remnant of evolutionary divergence within the globin superfamily[2][6]. Diseases associated with this locus include alpha-thalassemia, likely due to cluster-level effects rather than direct involvement of HBM as an expressed protein[1]. Summary of main issues: - Status as a protein-coding gene is disputed; formerly annotated as a pseudogene. - No confirmed detection of the encoded protein. - Not validated as a therapeutic target, biomarker, or disease gene in humans. - Not recognized as a major globin component, unlike alpha or beta globin subunits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemoglobin subunit mu (HBM).